AGTC Genomics

23/10/2026

𝗔𝗚𝗧𝗖 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗟𝗮𝘂𝗻𝗰𝗵𝗲𝘀 𝗦𝘁𝗮𝘁𝗲-𝗼𝗳-𝘁𝗵𝗲-𝗔𝗿𝘁 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗮𝗻𝗱 𝗘𝗽𝗶𝗴𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗣𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝘃𝗲 𝗮𝗻𝗱 𝗟𝗼𝗻𝗴𝗲𝘃𝗶𝘁𝘆 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲

AGTC Genomics is proud to launch genomics and epigenomics solutions supporting preventive and longevity medicine, including:

✅ Multi-cancer early detection
✅ Nutrigenomics and nutriepigenomics
✅ Pre-emptive pharmacogenomics
✅ Personal genomics and epigenomics
✅ Biological age assessment

By connecting these insights with reliable testing, accurate diagnosis and careful clinical interpretation, we aim to help healthcare teams personalise care and act earlier.

AGTC Genomics Launches State-of-the-Art Genomics and Epigenomics Solutions for Preventive and Longevity Medicine

22/10/2026

𝗪𝗵𝘆 𝘄𝗮𝗶𝘁 𝘂𝗻𝘁𝗶𝗹 𝘆𝗼𝘂 𝗳𝗲𝗲𝗹 𝘂𝗻𝘄𝗲𝗹𝗹 𝘁𝗼 𝘂𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱 𝘆𝗼𝘂𝗿 𝗵𝗲𝗮𝗹𝘁𝗵?

At AGTC Genomics, we help clinicians diagnose cancer, rare diseases and infectious diseases with timely, accurate results. Now, we’re taking another step forward—helping you understand your health risks and act earlier.

We’re proud to introduce a series of tests supporting preventive and longevity medicine:

✅ Multi-cancer early detection
✅ Nutrigenomics and nutriepigenomics
✅ Pre-emptive pharmacogenomics
✅ Personal genomics and epigenomics
✅ Biological age assessment

And many more to come!

From informing nutrition choices and medication decisions to supporting appropriate screening, these tests provide insights to help your healthcare team personalise your care.

Meaningful prevention starts with reliable testing, accurate diagnosis and careful clinical interpretation—turning results into informed action.

💙 Our goal is to help more people take charge of their health, stay independent and enjoy more healthy years with the people they love.

Learn more:
https://www.agtcgenomics.com/post/agtc-genomics-launches-state-of-the-art-genomics-and-epigenomics-solutions-for-preventive-and-longev

AGTC Genomics Launches State-of-the-Art Genomics and Epigenomics Solutions for Preventive and Longevity Medicine

21/10/2026

𝗔 𝗰𝗹𝗲𝗮𝗿𝗲𝗿 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀 𝗰𝗮𝗻 𝗰𝗵𝗮𝗻𝗴𝗲 𝘁𝗵𝗲 𝗰𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗶𝘁𝗵 𝗶𝗻𝗵𝗲𝗿𝗶𝘁𝗲𝗱 𝘀𝗸𝗶𝗻 𝗱𝗶𝘀𝗼𝗿𝗱𝗲𝗿𝘀.

For dermatologists, paediatricians, clinical geneticists and other specialists, overlapping skin manifestations can make diagnosis challenging—particularly when presentations are atypical or involve multiple organ systems.

AGTC Genomics’ Dermatology Genetic Test supports the investigation of suspected genodermatoses through a 330-gene comprehensive panel and 23 phenotype-focused sub-panels, with sequence and copy-number analysis.

Clinical indications include:

🧬 Skin fragility and cornification disorders—epidermolysis bullosa, congenital ichthyosis and palmoplantar keratoderma.

🧬 Pigmentation disorders—albinism, hypopigmentation and Waardenburg syndrome.

🧬 Ectodermal and hair disorders—ectodermal dysplasia and inherited hypotrichosis.

🧬 Vascular malformations and selected syndromic conditions.

🧬 Hereditary cancer predisposition syndromes with dermatological features—including basal cell nevus syndrome and xeroderma pigmentosum.

Why consider a molecular diagnosis?

When interpreted alongside clinical findings and family history, genetic results can help clarify the underlying condition, inform appropriate surveillance and multidisciplinary care, and support counselling on inheritance and reproductive risk. A confirmed diagnosis can also enable targeted testing for at-risk relatives.

Choose testing that fits your patient’s presentation: a focused sub-panel for a defined phenotype, or comprehensive analysis for complex and overlapping features.

✅ Testing in AGTC Genomics’ CAP-accredited NGS laboratory in Malaysia
✅ 7–14 business days turnaround from sample receipt
✅ EDTA blood, saliva, buccal swab or extracted DNA
✅ Pre- and post-test consultation and genetic counselling support

Have a patient with suspected inherited skin disease? Connect with our clinical team to discuss panel selection, sample requirements and ordering.

📩 [email protected]
📞 +6012 520 7981

21/10/2026

𝗪𝗵𝗲𝗻 𝗛𝗼𝗿𝗺𝗼𝗻𝗲 𝗧𝗲𝘀𝘁𝘀 𝗖𝗮𝗻𝗻𝗼𝘁 𝗘𝘅𝗽𝗹𝗮𝗶𝗻 𝘁𝗵𝗲 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀, 𝗖𝗼𝘂𝗹𝗱 𝗚𝗲𝗻𝗲𝘁𝗶𝗰𝘀 𝗛𝗼𝗹𝗱 𝘁𝗵𝗲 𝗠𝗶𝘀𝘀𝗶𝗻𝗴 𝗔𝗻𝘀𝘄𝗲𝗿?

Not every endocrine disorder can be fully explained by hormonal profiles, biochemical investigations, or imaging.

A young patient with diabetes may have monogenic diabetes rather than Type 1 or Type 2 diabetes. A child with unexplained short stature, a patient with severe early-onset obesity, or someone with abnormal puberty may have an underlying genetic disorder.

Without identifying the genetic cause, patients may face years of diagnostic uncertainty, inappropriate treatment, or missed opportunities for early intervention.

🧬 Introducing AGTC Genomics' Endocrinology Genetic Test — Advancing Precision Endocrine Medicine.

Our Next-Generation Sequencing (NGS) solution offers 654 genes across 24 phenotype-focused sub-panels, covering:

🔹 Diabetes: Monogenic diabetes, neonatal diabetes, hyperinsulinism
🔹 Obesity & Lipid Disorders: Monogenic obesity, familial dyslipidaemia
🔹 Growth & Pituitary Disorders: Short stature, growth hormone deficiencies
🔹 Thyroid & Parathyroid Disorders: Congenital hypothyroidism, hormone resistance
🔹 Adrenal Disorders: Congenital adrenal hyperplasia, hyperaldosteronism
🔹 Reproductive Endocrinology: Disorders of s*x development, delayed puberty, premature ovarian failure
🔹 Endocrine Neoplasia: Multiple endocrine neoplasia syndromes

Why Does Genetic Diagnosis Matter?

✅ Improve diagnostic accuracy in complex endocrine conditions
✅ Guide genotype-specific treatment decisions
✅ Identify hereditary disorders requiring family screening
✅ Support personalized monitoring and long-term management

Why AGTC Genomics?

🏅 CAP-accredited genomics laboratory
🧬 Comprehensive and phenotype-focused NGS panels
⏱️ 7–14 business days turnaround
🤝 Genetic counselling and clinical interpretation support

Precision endocrinology begins with understanding the genetic cause of disease.

At AGTC Genomics, we help clinicians move beyond biochemical diagnosis towards molecularly informed patient care.

📩 Explore our Endocrinology Genetic Test with AGTC Genomics.

🌐 www.agtcgenomics.com
📧 [email protected]

18/10/2026

𝗔𝗚𝗧𝗖 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗘𝘅𝗽𝗮𝗻𝗱𝘀 𝗣𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘀𝗲𝗱 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗶𝗻 𝗩𝗶𝗲𝘁𝗻𝗮𝗺 🇻🇳🧬

AGTC Genomics is working with MedArmor Vietnam to bring genomic insights closer to personalised preventive care.

MedArmor is a high-technology health screening and care centre that applies molecular biotechnology and artificial intelligence to assess multiple layers of health indicators, understand emerging health trends and support personalised advice for long-term wellbeing.

Combining AGTC Genomics’ expertise in genomic testing and interpretation with MedArmor’s approach to comprehensive health assessment creates opportunities to help individuals better understand their health and make informed decisions with their healthcare professionals.

The value of genomics extends beyond a test result. When interpreted alongside clinical findings, family history and lifestyle, genomic information can support more personalised discussions about prevention, screening and follow-up care.

Working with MedArmor marks another step in AGTC Genomics’ regional expansion—connecting our genomics expertise with local healthcare delivery to support more proactive, personalised care in Vietnam and across Southeast Asia.

From genomic insights to informed health decisions.

AGTC Genomics Collaborates with MedArmor Vietnam to Advance Personalised Preventive Healthcare

15/10/2026

𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗱𝗼𝗲𝘀 𝗻𝗼𝘁 𝘀𝘁𝗼𝗽 𝗮𝘁 𝗴𝗲𝘁𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝗔𝗦𝗧𝗤 𝗳𝗶𝗹𝗲𝘀. 𝗡𝗲𝗶𝘁𝗵𝗲𝗿 𝗱𝗼 𝘄𝗲.

Sequencing generates data. Answering a critical research question requires a clear hypothesis, thoughtful study design, robust analysis and meaningful biological interpretation.

At AGTC Genomics, we work alongside investigators throughout that journey—from the early ideation of a research project to advanced bioinformatics analyses that connect genomic findings with the questions that matter.

Our role begins before a sample reaches the sequencer:

🧬 𝗥𝗲𝗳𝗶𝗻𝗶𝗻𝗴 𝘁𝗵𝗲 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗾𝘂𝗲𝘀𝘁𝗶𝗼𝗻
Helping investigators translate an idea into a focused, testable hypothesis.

🔬 𝗗𝗲𝘀𝗶𝗴𝗻𝗶𝗻𝗴 𝘁𝗵𝗲 𝗿𝗶𝗴𝗵𝘁 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵
Aligning sample selection, sequencing strategy, coverage and analytical methods with the study’s objectives.

💻 𝗧𝘂𝗿𝗻𝗶𝗻𝗴 𝗱𝗮𝘁𝗮 𝗶𝗻𝘁𝗼 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲
Moving beyond raw reads to quality assessment, variant discovery, annotation, prioritisation and analyses tailored to the research question.

🤝 𝗜𝗻𝘁𝗲𝗿𝗽𝗿𝗲𝘁𝗶𝗻𝗴 𝗳𝗶𝗻𝗱𝗶𝗻𝗴𝘀 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿
Discussing biological relevance, recognising limitations and identifying opportunities for validation and further investigation.

Here, we are sharing whole-genome sequencing analysis methods with fellow research investigators, exploring how analytical choices can help address their specific research questions.

𝗪𝗵𝘆 𝗱𝗼𝗲𝘀 𝘁𝗵𝗶𝘀 𝗺𝗮𝘁𝘁𝗲𝗿? Because even high-quality sequencing data can fall short of its potential when the study design, analytical workflow and interpretation are disconnected. A FASTQ file contains sequencing reads; it does not, by itself, explain which findings matter or what they mean.

The value of genomics lies in connecting those steps—so that data can support credible conclusions and guide the next discovery.

AGTC Genomics is more than a DNA sequencing service provider. We are genomics experts and an end-to-end solutions partner—from research ideas to biological insights.

15/10/2026

𝗔𝗚𝗧𝗖 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀, 𝗜𝗠𝗨 𝗨𝗻𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 𝗮𝗻𝗱 𝗠𝗢𝗦𝗧𝗔 𝗣𝗮𝗿𝘁𝗻𝗲𝗿 𝘁𝗼 𝗖𝗼𝗻𝗱𝘂𝗰𝘁 𝗢𝗻𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗟𝗮𝗿𝗴𝗲𝘀𝘁 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗦𝘁𝘂𝗱𝗶𝗲𝘀 𝗼𝗻 𝗧𝗼𝗰𝗼𝘁𝗿𝗶𝗲𝗻𝗼𝗹𝘀 𝗳𝗼𝗿 𝗛𝗲𝗮𝗹𝘁𝗵𝘆 𝗔𝗴𝗲𝗶𝗻𝗴

AGTC Genomics has signed a tripartite MoU with IMU University and the Malaysian Oil Scientists’ and Technologists’ Association (MOSTA) to advance palm oil R&D—with a major focus on the geroprotective potential of palm-derived tocotrienols.

The signing took place at OFIC 2026, witnessed by YB Datuk Seri Dr. Noraini Ahmad, Minister of Plantation and Commodities.

At the heart of this partnership is a planned study envisaged as one of the largest clinical investigations specifically examining tocotrienols for healthy ageing.

Tocotrienols have been studied for their antioxidant and cell-protective properties, including their potential effects on oxidative stress and DNA damage. Our next step is to strengthen the clinical evidence: can these promising biological effects translate into meaningful benefits for healthy ageing?

For Malaysia, this research also carries economic significance. Palm oil supports livelihoods, employment and export earnings. Developing scientifically substantiated, higher-value palm-derived products can open new opportunities in nutrition and health.

This collaboration builds on AGTC Genomics’ wider oil palm research with multiple partners—from whole-genome sequencing to soil microbiome studies aimed at improving crop quality, yield and soil health.

By bringing together genomics, academic research and oils and fats expertise, we aim to connect agricultural innovation with human health—and create greater value from one of Malaysia’s most important resources.

Read the full announcement to learn more about the partnership and its research ambitions.

AGTC Genomics, IMU University and MOSTA Partner to Conduct One of the Largest Clinical Studies on Tocotrienols for Healthy Ageing

08/10/2026

𝗛𝗼𝘄 𝗶𝘀 𝗴𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗰𝗵𝗮𝗻𝗴𝗶𝗻𝗴 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗻𝘂𝘁𝗿𝗶𝘁𝗶𝗼𝗻?

At the recent Entrepreneurial Leadership Forum: “Scaling Innovation for a One Health Future,” Samantha Wong, Chief Dietitian at AGTC Genomics, shared how nutrigenomics, nutriepigenomics and polygenic risk scores (PRS) are beginning to transform modern dietetics.

The same diet does not work equally well for everyone.

Our genes can influence how we respond to nutrients, fats, glucose, caffeine and other dietary factors, while lifestyle and diet can also influence gene regulation through epigenetic mechanisms.

With advances such as PRS, dietitians may be able to better understand an individual’s inherited susceptibility to conditions such as obesity, diabetes, dyslipidaemia and cardiovascular disease — allowing earlier and more targeted nutritional intervention.

The future of personalized nutrition may increasingly combine:

Genomics + PRS + biomarkers + microbiome + lifestyle + dietary behaviour

The goal is not a rigid “DNA diet”, but more personalized, preventive and evidence-informed nutrition.

At AGTC Genomics, we believe this represents an important step towards helping individuals better understand their health risks and make more informed dietary and lifestyle choices.

https://www.agtcgenomics.com/post/agtc-genomics-chief-dietitian-samantha-wong-highlights-the-future-of-personalized-nutrition

AGTC Genomics Chief Dietitian Samantha Wong Highlights the Future of Personalized Nutrition

06/10/2026

𝗖𝗮𝗻 𝘄𝗲 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗲 𝗶𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗳𝗶𝗿𝘀𝘁 𝗴𝘂𝗲𝘀𝘀𝗶𝗻𝗴 𝘄𝗵𝗶𝗰𝗵 𝗽𝗮𝘁𝗵𝗼𝗴𝗲𝗻 𝘁𝗼 𝘁𝗲𝘀𝘁 𝗳𝗼𝗿?

At the recent Malaysia Microbiome Meeting 2026, AGTC Genomics presented its latest findings on Clinical Metagenomics — an NGS-based approach for broad, unbiased pathogen detection.

The study showed high concordance with conventional methods such as bacterial culture and PCR, while offering an important advantage: the ability to screen broadly for bacteria, viruses, fungi and parasites in a single test.

Instead of asking: “What pathogen should I test for?”

Clinical Metagenomics helps move towards: “What is actually causing the infection?”

AGTC Genomics’ current workflow covers approximately 700 clinically relevant pathogens, with a turnaround time of less than 24 hours, making it especially useful for difficult cases such as culture-negative infections, critically ill patients, atypical infections and cases where prior antibiotics may have reduced culture yield.

Importantly, the goal is not simply to detect more organisms, but to identify the most clinically relevant pathogen by combining sequencing results with microbial abundance, specimen type, symptoms and other clinical findings.

To further advance this work, AGTC Genomics, IMU University and UMMC have recently secured a joint research fund from MOSTI to support implementation across hospitals and to develop a local infectious disease genomic database and antimicrobial resistance reference database for Malaysia.

This is an important step towards more rapid, evidence-based and precision-driven infectious disease diagnostics.

One sample. Broad detection. Rapid interpretation. Actionable treatment.

https://www.agtcgenomics.com/post/agtc-genomics-presents-latest-clinical-metagenomics-findings-at-malaysia-microbiome-meeting-2026

NGS-based approach demonstrates high concordance with conventional microbiology while enabling broad, unbiased detection of bacterial, viral, fungal and parasitic pathogens in under 24 hoursKUALA LUMPUR, 3 October 2026 — AGTC Genomics presented its latest findings on Clinical Metagenomics for infe...

29/09/2026

🧬 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗴𝗲𝗻𝗼𝗺𝗶𝗰𝘀. 𝗖𝗹𝗲𝗮𝗿𝗲𝗿 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀.

OncoDx™ brings comprehensive cancer genomic profiling into a single test — detecting multiple classes of genomic alterations and key signatures that may influence treatment decisions.

With results in 7–14 working days, clinicians receive clear, actionable genomic information to support more personalized cancer care.

Actionable results. Clear reports. Better outcomes.